Mallinckrodt’s liver disease drug terlipressin edges FDA advisory panelAn FDA advisory committee has narrowly voted in favour of approval of Mallinckrodt’s terlipressin for hepatorenal syndrome type Share XMallinckrodt’s liver disease drug terlipressin edges FDA advisory panelhttps://pharmaphorum.com/news/mallinckrodts-liver-disease-drug-terlipressin-edges-fda-advisory-panel/
Mallinckrodt, Novoteris’ nitric oxide will start COVID-19 trialMallinckrodt and Novoteris have been given a green light by Health Canada to start a pilot study of Share XMallinckrodt, Novoteris’ nitric oxide will start COVID-19 trialhttps://pharmaphorum.com/news/mallinckrodt-novoteris-nitric-oxide-will-start-covid-19-trial/
Mallinckrodt proposes $1.6bn deal to settle opioid litigationMallinckrodt is placing a $1.6 billion settlement package on the table as it tries to bring litigation related Share XMallinckrodt proposes $1.6bn deal to settle opioid litigationhttps://pharmaphorum.com/news/mallinckrodt-proposes-1-6bn-deal-to-settle-opioid-litigation/
Purdue preps bankruptcy as opioid settlement bid stumbles; reportPurdue Pharma is reported to be preparing to file for bankruptcy amid resistance to its $10-$12 billion offer Share XPurdue preps bankruptcy as opioid settlement bid stumbles; reporthttps://pharmaphorum.com/news/purdue-preps-bankruptcy-as-opioid-settlement-bid-stumbles-report/
Facing opioid liability risk, Mallinckrodt stalls generics splitMallinckrodt has put plans to separate its specialty generics business on hold while it gauges the impact of Share XFacing opioid liability risk, Mallinckrodt stalls generics splithttps://pharmaphorum.com/news/facing-opioid-liability-risk-mallinckrodt-stalls-generics-split/
Troubled Mallinckrodt pays $1.2bn for SucampoSpecialist pharma company Mallinckrodt announced on 26 December that it is to acquire Sucampo Pharmaceuticals for around $1.2 Share XTroubled Mallinckrodt pays $1.2bn for Sucampohttps://pharmaphorum.com/news/troubled-mallinckrodt-pays-1-2bn-sucampo/
Mallinckrodt pays US authorities $100m in pricing casePrice of epilepsy drug increased 85,000% since 2001, says FTC. Share XMallinckrodt pays US authorities $100m in pricing casehttps://pharmaphorum.com/news/mallincrodt-pays-us-authorities-100m-pricing-case/